with eyes set on the future

Investment
Innovation
Internationalization
Partnerships
Quality

bluepharma
Who we are

Bluepharma is a privately owned portuguese **pharmaceutical group**.

Through the entrepreneurship of its promoters, Bluepharma Group currently comprises 20 innovative companies that cover all stages of the pharmaceutical industry value chain.

Bluepharma’s R&D-based strategy allowed to target the most demanding markets.

- **over 100** Worldwide territories
- **more than 160** Worldwide clients
- **88%** Export rate

Bluepharma offers an integrated approach, including innovative research as well as the development, manufacturing and commercialization of medicines. This has proven to be determinant in our differentiation and competitiveness.

State of the art equipment and **highly qualified** team.
Our integrated approach

Bluepharma offers an integrated approach, providing support on all steps of the product development, from R&D to market.

Why work with us

- Leading contract developer and manufacturer, with an integrated approach.
- Full-scale development projects with a proven track-record in international product launches.
- Long-term partnerships, based on time to market, cost-awareness and a result-driven strategy.
- R&D Centers and Manufacturing plants in Portugal.
- Capability to develop and manufacture high potency products.
- High quality standards recognized by several international regulatory authorities.
Where we are

Bluepharma collaborates globally with major pharmaceutical companies through licensing of its own technology or distribution of its own brand.

Our numbers

- 700 Employees
- 100 Countries
- 60 INNs Produced
- 160 End Customers
- 25% R&D Investment Over Turnover

Our own brand

- bluepharma GENERICOS

- 116 INNs Commercialized
- 11 Therapeutic Areas
Innovative Solutions

Oromucosal delivery

Oral Thin Films
BlueOS®

Buccal Sprays
BlEase™

Oral Dispersible Tablet

Development of novel and versatile Oromucosal delivery formulations, aiming to provide solutions to unmet medical needs through Value Added Medicines.

OSD Fixed-Dose Combinations

Development of advanced formulations that aim the modulation of the release profile, overcome barriers such as incompatibilities between molecules and increase of the stability, including multi-layer tablets, micro tablets, capsule-in-capsule and Hot Melt Extrusion technologies.

Complex Steriles

Lipid nanoparticles (LNP)
Polymer-based microparticles

Development of Complex Sterile formulations, that offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.

Luzitin

Research and development of novel therapeutic strategies for cancer. The lead compound, Redaporfin, has been granted Orphan Drug Designation (ODD) from both EMA and FDA and achieved successful results from its phase I–IIa clinical trial in advanced head and neck cancer.

TREAT-U

Research and development of innovative targeted nanoparticles (PEGASEMP®) capable of targeting two distinct cell populations in the tumor: the cancer cells and the blood vessels that nurture the tumor. Orphan Drug Designation (ODD) has been granted to PEGASEMP® from both EMA and FDA. PEGASEMP® has completed a formal non-clinical program and preparation of entry-into-humans study is undergoing.

+25%
R&D INVESTMENT OVER TURNOVER
Our Value

Bluepharma’s aim is to **create value through innovation.**

This is achieved in dedicated R&D facilities that offer services ranging from the formulation and analytical development to the design of novel delivery platforms, as well as dedicated facilities for high potency drugs.
INTEGRATED APPROACH
INTERNATIONAL TRACK RECORD
EXPERTISE IN CONTRACT DEVELOPMENT
EXTENSIVE AND DIFFERENTIATED PORTFOLIO

Bluepharma’s facilities are EU-GMP certified and approved by:
- SFDA (Kingdom of Saudi Arabia)
- ANVISA (Brazil)
- MFDS (Republic of Korea)
- Minpromtorg (Russian Federation)
- MOH Libya
- TMMDA (Turkey)

We are registered in Iraq, Jordan, Kurdistan, Taiwan, UAE and Vietnam.

S. Martinho do Bispo • 3045–016 Coimbra • PORTUGAL
Tel. +351 239 800 300 • Fax +351 239 800 333
E-mail: bluepharma@bluepharma.pt

www.bluepharmagroup.com